Skip to main
  1. Stocks
  2. Kazia Therapeutics
  3. Forecast
KZIA

Kazia Therapeutics (KZIA) Stock Forecast & Price Target

Kazia Therapeutics (KZIA) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kazia Therapeutics is attractive because paxalisib targets a clinically validated PI3K/AKT/mTOR pathway with a differentiated oral, brain-penetrant profile that could matter in CNS-involved cancers where many competitors fall short. Early clinical signals are compelling, including an 83% ORR in frontline TNBC patients and meaningful biomarker evidence of reduced circulating tumor cell clusters and exhausted T cells, while broader programs in GBM, HR+/HER2- breast cancer, and pMMR CRC create multiple shots on goal. Financially, the company reported AU$69.5M in cash in FY 1H:26 and a modeled pro-forma AU$102M in FY 1H:27, which supports development runway and lowers near-term funding pressure.

Bears say

Kazia Therapeutics is weighed down by a weak clinical and regulatory foundation for paxalisib, since the GBM program did not meet the prespecified criteria to advance to Stage 2 and the FDA said the existing data were insufficient for an NDA, implying that substantially more evidence and capital are needed before any approval path is credible. The safety and efficacy profile also looks constraining, with common toxicities such as hyperglycemia, stomatitis, fatigue, and GI effects, plus a 46.7% discontinuation rate and 80% of patients requiring dose reductions or interruptions, while the observed OS benefit in newly diagnosed GBM was modest and recurrent disease data were worse than control. Commercially, the company faces a difficult, crowded oncology landscape where TNBC pathway inhibitors have repeatedly failed in Phase III, meaning Kazia must still prove paxalisib can differentiate itself enough to justify further financing, execution risk, and potential dilution.

Kazia Therapeutics (KZIA) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kazia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Kazia Therapeutics (KZIA) Analyst Forecast & Price Prediction

Get the latest Kazia Therapeutics (KZIA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Kazia Therapeutics (KZIA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kazia Therapeutics (KZIA) Forecast

Analysts have given Kazia Therapeutics (KZIA) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Kazia Therapeutics (KZIA) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kazia Therapeutics (KZIA)


Kazia Therapeutics (KZIA) Analyst Forecast & Price Prediction

Get the latest Kazia Therapeutics (KZIA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Kazia Therapeutics (KZIA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KZIA stock data and trends